Threshold Pharmaceuticals Announces Results of Two New Preclinical Studies Evaluating Novel Combinations of TH-302 With Immun...
April 03 2014 - 7:00AM
Marketwired
Threshold Pharmaceuticals Announces Results of Two New Preclinical
Studies Evaluating Novel Combinations of TH-302 With Immunotherapy,
Antiangiogenic Therapy, and Radiotherapy to Be Presented at AACR
Annual Meeting 2014
SOUTH SAN FRANCISCO, CA--(Marketwired - Apr 3, 2014) - Threshold
Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that results
of two new preclinical studies evaluating novel combinations of
TH-302, its investigational hypoxia-targeted drug, with
immunotherapy, antiangiogenic therapy, and radiotherapy for the
potential treatment of cancer will be highlighted in poster
presentations at the American Association for Cancer Research
(AACR) Annual Meeting 2014 taking place April 5 - 9, in San Diego,
California.
"The rapidly evolving landscape in discovery and development of
new cancer therapeutics includes exploring novel combinations of
different treatment modalities such as targeted therapies,
immunotherapy, radiotherapy and chemotherapeutic agents," said
Charles Hart, Ph.D., Vice President of Biology at Threshold. "We
believe that targeting the hypoxic tumor microenvironment, which
harbors cells that are resistant to conventional therapies and
prone to metastasize, may be an important component of new
combination approaches to treating cancer. In Phase 1 and 2
clinical trials, TH-302 has demonstrated encouraging anti-tumor
activity when used as a single agent or as part of combination
regimens. We believe that data from the preclinical studies, to be
presented at AACR, warrant further evaluation of additional
potential therapeutic combinations using TH-302."
Poster presentation details:
Abstract #629 (Poster #4): Combination hypoxia-specific
chemotherapy and immunotherapy of prostate cancer; 1:00 PM - 5:00
PM Pacific Time on Sunday, April 6, 2014, in Hall A-E, Poster
Section 27.
Abstract #5447 (Poster #23): Targeting vascular endothelial
growth factor A and tumor hypoxia combined with radiation
eradicates sarcomas through destruction of tumor vasculature and
thwarting of the hypoxic response; 8:00 AM - 12:00 PM Pacific Time
on Wednesday, April 9, 2014, in Hall A-E, Poster Section 30.
About TH-302 TH-302 is an investigational hypoxia-targeted drug
that is designed to be activated under tumor hypoxic conditions, a
hallmark of many cancers. Areas of low oxygen levels (hypoxia) in
solid tumors are due to insufficient blood supply as a result of
aberrant vasculature. Similarly, the bone marrow of patients with
hematological malignancies has also been shown, in some cases, to
be severely hypoxic.
TH-302 is currently under evaluation in two Phase 3 trials: one
in combination with doxorubicin versus doxorubicin alone in
patients with soft tissue sarcoma, and the other in combination
with gemcitabine versus gemcitabine and placebo in patients with
advanced pancreatic cancer (MAESTRO). Both Phase 3 trials are
being conducted under Special Protocol Agreements with the U.S.
Food and Drug Administration (FDA). The FDA and the European
Commission have granted TH-302 Orphan Drug Designation for the
treatment of soft tissue sarcoma and pancreatic cancer. TH-302
is also being investigated in hematological malignancies and in
combination with other therapies in a variety of solid tumors.
Threshold has a global license and co-development agreement for
TH-302 with Merck KGaA, Darmstadt, Germany, which includes an
option for Threshold to co-commercialize in the U.S.
About Threshold Pharmaceuticals Threshold Pharmaceuticals, Inc.
is a biotechnology company focused on the discovery and development
of drugs targeting tumor hypoxia, the low oxygen condition found in
microenvironments of most solid tumors as well as the bone marrows
of some hematologic malignancies. This approach offers broad
potential to treat a variety of cancers. By selectively
targeting tumor cells, we are building a pipeline of drugs that
hold promise to be more effective and less toxic to healthy tissues
than conventional anticancer drugs. For additional
information, please visit our website (www.thresholdpharm.com).
Forward-Looking Statements Except for statements of historical
fact, the statements in this press release are forward-looking
statements, including statements regarding the potential
therapeutic uses and benefits of TH-302, including TH-302's
potential to be a component of new combination approaches to
treating cancer, and statements regarding the TH-302 clinical
development program, including conduct of ongoing clinical trials
and the potential development of new therapeutic combinations using
TH-302. These statements involve risks and uncertainties that
can cause actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties
include, but are not limited to: the ability of Threshold and
Merck KGaA, Darmstadt, Germany, to enroll or complete
TH-302 clinical trials; the time and expense required to
conduct such clinical trials and analyze data; issues arising in
the regulatory or manufacturing process and the results of such
clinical trials (including product safety issues and efficacy
results); the risk that preclinical studies in animal models of
disease may not accurately predict the result of human clinical
trials of TH-302; Threshold's and Merck KGaA's (Darmstadt,
Germany) dependence on single source suppliers, including the
risk that these single source suppliers may be unable to meet
clinical supply demands for TH-302 which could significantly delay
the development of TH-302; risks related to Threshold's dependence
on its collaborative relationship with Merck KGaA, Darmstadt,
Germany, including its dependence on decisions by Merck KGaA,
Darmstadt, Germany regarding the amount and timing of resource
expenditures for the development of TH-302; and Threshold's need
for and the availability of resources to develop TH-302 and to
support Threshold's operations. Further information regarding these
and other risks is included under the heading "Risk Factors" in
Threshold's Annual Report on Form 10-K, which has been filed with
the Securities and Exchange Commission on March 6, 2014 and is
available from the SEC's website (www.sec.gov) and on our website
(www.thresholdpharm.com) under the heading "Investors." We
undertake no duty to update any forward-looking statement made in
this news release.
Contact Laura Hansen, Ph.D. Senior Director, Corporate
Communications Phone: 650-474-8206 E-mail:
lhansen@thresholdpharm.com
Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From Apr 2023 to Apr 2024